Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.61 |
| ▸ | YAP1 | P46937 | 1/20 | 0.58 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.58 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | IDH2 | P48735 | 2/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921484 | 0.88 | MAPT (0.77) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL20693799 | 0.81 | ALDH1A1 (0.69) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL11566545 | 0.81 | ALDH1A1 (0.68) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL1463167 | 0.80 | KDR (0.73) | MAPTRAB9AALDH1A1GAARXFP1 | |
| SCHEMBL20551660 | 0.80 | GAA (0.67) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL29414647 | 0.80 | MAPT (1.00) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL10215929 | 0.80 | GAA (0.67) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4064881 | 0.80 | MAPT (1.00) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL394991 | 0.80 | KIF11 (0.70) | MAPTRAB9AALDH1A1GAASMN1; SMN2 | |
| Flufenamic Acid SCHEMBL17497 | 0.78 | RXFP1 (0.75) | ALDH1A1RXFP1YAP1TEAD4TEAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| CN-101378750-B | Indolone compounds useful to treat cognitive impairment | HELICON THERAPEUTICS INC | 2012-07-18 | — | — | CN | disclosed |
| CN-101484159-A | Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist | HELICON THERAPEUTICS INC (US) | 2009-07-15 | — | — | CN | disclosed |
| CN-101378750-A | Indolone compounds useful to treat cognitive impairment | HELICON THERAPEUTICS INC (US) | 2009-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | MAPT 110/4885RAB9A 1351/4885ALDH1A1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.